Determination of bleeding risk using genetic markers in patients taking phenprocoumon

European Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2003, Pages 213-219

  Hummers Pradier, Eva ^a   Hess, Stephan ^a   Adham, Ibrahim M ^a   Papke, Thomas ^a   Pieske, Burkert ^a   Kochen, Michael M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Anticoagulants; Cytochrome P 450 CYP2C9 polymorphism; General practice; Genetic markers; Phenprocoumon

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; CYTOCHROME P450 2C9; PHENPROCOUMON; WARFARIN;

ADULT; AGED; ALLELE; ARTICLE; BLEEDING; BLOOD SAMPLING; CONFIDENCE INTERVAL; DRUG HYPERSENSITIVITY; FEMALE; GENE MUTATION; GENERAL PRACTITIONER; GENETIC MARKER; GENETIC VARIABILITY; GERMANY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC MARKERS; GENOTYPE; HEMORRHAGE; HUMANS; MIDDLE AGED; PHENPROCOUMON; POLYMORPHISM, GENETIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0043164978     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0580-8     Document Type: Article

References (37)

1. Kuijer PM, Hutten BA, Prins MH, Buller HR (1999) Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 159:457-460
2. Schwabe U (2000) Anticoagulants. In: Schwabe U, Paffrath D (eds) Drug prescribing report 2000 [in German]. Springer, Berlin, Heidelberg, pp 186-194
3. rd edn. Lippincott, Philadelphia, pp 1567-1583
4. Kristiansen C, Lassen JF, Dahler-Eriksen BS, Dahler-Eriksen K, Larsen TB, Brandslund I (2000) Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 98:157-163
5. Harder S, Thurmann P (1996) Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 30:416-444
6. He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF (1999) Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 372:16-28
7. Brockmöller J, Kirchheiner J, Meisel C, Roots I (2000) Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 1:125-151
8. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
9. Margaglione M, Colaizzo D, D'Andrea G et al. (2000) Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 84:775-778
10. Higashi MK, Veenstra DL, Kondo LM et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287:1690-1698
11. Fitzmaurice DA, Hobbs FD, Murray ET (1998) Primary care anticoagulant clinic management using computerized decision support and near patient International Normalized Ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 15:144-146
12. Hobbs FD, Fitzmaurice DA (1997) Where should oral anticoagulation monitoring take place? Br J Gen Pract 47:479-480
13. Baglin T (2001) Avoiding overanticoagulation: pharmacogenomics or pragmatism? Thromb Haemost 85:945-946
14. Holtzman NA, Marteau TM (2001) Will genetics revolutionize medicine? N Engl J Med 343:141-144
15. Emery J, Hayflick S (2001) The challenge of integrating genetic medicine into primary care. BMJ 322:1027-1030
16. Wolf CR, Smith G, Smith RL (2000) Science, medicine, and the future: pharmacogenetics. BMJ 320:987-990
17. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F (1999) Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 254:628-631
18. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 52:447-450
19. Scottish Intercollegiate Guidelines Network (1999) Antithrombotic therapy. A national clinical guideline. Edinburgh (Scotland). SIGN publication no. 36. http://www.guideline.gov/VIEWS/full_text.asp?guideline=002133 (accessed on 30 December 2002)
20. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR (1996) Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6:429-439
21. SAS Institute (1999) SAS/STAT. User's guide, version 8, vol 3. SAS Institute, Cary, NC
22. Sackett DL, Richardson WS, Rosenberg W, Haynes RB (1997) Evidence-based medicine. Churchill Livingstone, New York
23. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210
24. Mannucci PM (1999) Genetic control of anticoagulation. Lancet 353:688-689
25. Verstuyft C, Morin S, Robert A et al. (2001) Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 11:735-737
26. Halkin H, Lubetsky A (1999) Warfarin dose requirement and CYP2C9 polymorphisms. Lancet 353:1972-1973
27. Kortke H, Korfer R (2001) International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous? Ann Thorac Surg 72:44-48
28. Cromheecke ME, Levi M, Colly LP et al. (2000) Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. Lancet 356:97-102
29. Walton RT, Harvey E, Dovey S, Freemantle N (2001) Computerised advice on drug dosage to improve prescribing practice. Cochrane Database Syst Rev 1
30. Bell-Syer SE, Moffett JA (2000) Recruiting patients to randomized trials in primary care: principles and case study. Fam Pract 17:187-191
31. Wilson S, Delaney BC, Roalfe A et al. (2000) Randomised controlled trials in primary care: case study. BMJ 321:24-27
32. Beyth RJ (2001) Hemorrhagic complications of oral anticoagulant therapy. Clin Geriatr Med 17:49-56
33. Akker M van den, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA (1998) Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 51:367-375
34. Veehof L, Stewart R, Haaijer-Ruskamp F, Jong BM (2000) The development of polypharmacy. A longitudinal study. Fam Pract 17:261-267
35. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819
36. Morin S, Loriot MA, Poirier JM et al. (2000) Is diclofenac a valuable CYP2C9 probe in humans? Eur J Clin Pharmacol 56:793-797
37. Yasar U, Forslund-Bergengren C, Tybring G et al. (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89-98